Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of pre ... more
Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks
05-15-2006: Celera Genomics, an Applera Corporation business, the University of California, San Francisco (UCSF), Cleveland Clinic, Case Western Reserve University and Brigham Young University, announced a publication describing two novel genetic markers associated with an increased risk for myocardial infarction (MI), or heart attack. Neither of the two gene variants, VAMP8 and HNRPUL1, has previously been associated with MI. This paper will appear in "Arteriosclerosis, Thrombosis and Vascular Biology".
The retrospective research study performed in samples from over 2,000 individuals in three case-control studies identified two genetic variations known as single nucleotide polymorphisms (SNPs) that are associated with increased risk for early-onset heart attack. The study identified novel genetic markers in two genes: VAMP8, which is involved in platelet aggregation; and HNRPUL1, which encodes a ribonuclear protein.
Celera evaluated DNA samples from more than 2,000 individuals in three studies to compare patterns of genetic variation in people with a history of early-onset MI to those with no history of MI. The results were significant in all three studies.
The key finding of the study was that variants of the VAMP8 and HNRPUL1 genes were associated with early-onset MI and had the same risk variants in all three studies. These genetic markers were identified through a genome-wide study of an initial 11,647 single nucleotide polymorphisms (SNPs) in 7,136 genes, focusing on SNPs that could influence gene function in order to increase the likelihood of identifying disease-causing gene variants. These were tested for association with early-onset MI in three case-control study studies with a total of 821 cases and 1,200 controls.
Facts, background information, dossiers
More about Celera Genomics
-
News
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test
Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1). The test Ce ... more
Celera and Collaborators Discover Genetic Markers Associated with Early-onset Heart Attacks
Celera Genomics, an Applera Corporation business, the University of California, San Francisco (UCSF), Cleveland Clinic, Case Western Reserve University and Brigham Young University, announced a publication describing two novel genetic markers associated with an increased risk for myocardial ... more
More about Applera
-
News
Applied Biosystems, 454 Life Sciences and Illumina Join 1000 Genomes Project
Leaders of the 1000 Genomes Project announced that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: Appl ... more
BIOTECON Diagnostics signs license agreement with Applera Corporation
Applera and BIOTECON Diagnostics (BCD) announced a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. In ... more
Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland. The test, known as CRS7, is the first clinical test capable of pre ... more
Most read news
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2SCHOTT Instruments has changed its name to SI Analytics
- 3VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
- 4SGS Minerals Services opens new lab in Chennai, India
- 5MDS Sciex Opens Manufacturing Facility in Singapore
- 6Sartorius opens new plant in India
- 7Affymetrix and eBioscience Amend Definitive Merger Agreement
- 8Fluidigm China Opens Its Doors
- 9Thermo Fisher Scientific Acquires NanoDrop Technologies
- 10PIAB announces new Chief Executive Officer
News from cooperation
- Agilent Technologies and Universiti Putra Malaysia to Collaborate on Halal F ...
- Agilent Technologies and FDA Collaborate to Improve Testing for Salmonella
- Malvern Instruments and Postnova Analytics co-operate to deliver combined so ...
- Analytik Jena and SOTAX announce cooperation in dissolution systems
- Sartorius Stedim Biotech and Refine Technology Announce Cooperation
Last viewed
- Warnex first to launch quantitative PCR test for food testing - - Quantification of Campylobacter Within 3 Hours Using Real-Time PCR
- 1,000 times higher sensitivity for doping testing available now - - Chimera Biotec and German Sports University developed a new and extremely sensitive technology for anti-doping testing
- Yokogawa Analytical Systems to become wholly owned subsidiary of Agilent Technologies -
- Development Cooperation for New Molecular Diagnostic Assays between Bruker Daltonik, PANATecs and the University of Goettingen -
- Charles River Laboratories Enters Worldwide Collaboration with Deltagen -
